304 related articles for article (PubMed ID: 8101460)
21. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology.
Steen VM; Andreassen OA; Daly AK; Tefre T; Børresen AL; Idle JR; Gulbrandsen AK
Pharmacogenetics; 1995 Aug; 5(4):215-23. PubMed ID: 8528268
[TBL] [Abstract][Full Text] [Related]
22. Phenotype/genotype relationships for the cytochrome P450 enzyme CYP2D6 in rheumatoid arthritis: influence of drug therapy and disease activity.
Beyeler C; Daly AK; Armstrong M; Astbury C; Bird HA; Idle JR
J Rheumatol; 1994 Jun; 21(6):1034-9. PubMed ID: 7932410
[TBL] [Abstract][Full Text] [Related]
23. PCR-based CYP2D6 genotyping for Finnish lung cancer patients.
Hirvonen A; Husgafvel-Pursiainen K; Anttila S; Karjalainen A; Pelkonen O; Vainio H
Pharmacogenetics; 1993 Feb; 3(1):19-27. PubMed ID: 8097947
[TBL] [Abstract][Full Text] [Related]
24. Quinidine inhibition of debrisoquine S(+)-4- and 7-hydroxylations in Chinese of different CYP2D6 genotypes.
Bertilsson L; Meese CO; Yue QY; Dahl ML; Ingelman-Sundberg M; Johansson I; Säwe J; Eichelbaum M
Pharmacogenetics; 1993 Apr; 3(2):94-100. PubMed ID: 8100167
[TBL] [Abstract][Full Text] [Related]
25. [Study of transcription of the human cytochrome P450IID6 gene by polymerase chain reaction].
Krynetskiĭ EIu; Kovaleva IE
Mol Biol (Mosk); 1992; 26(4):943-8. PubMed ID: 1435785
[TBL] [Abstract][Full Text] [Related]
26. Identification of the primary gene defect at the cytochrome P450 CYP2D locus.
Gough AC; Miles JS; Spurr NK; Moss JE; Gaedigk A; Eichelbaum M; Wolf CR
Nature; 1990 Oct; 347(6295):773-6. PubMed ID: 1978251
[TBL] [Abstract][Full Text] [Related]
27. DNA haplotype dependency of debrisoquine 4-hydroxylase (CYP2D6) expression among extensive metabolisers.
Mura C; Panserat S; Vincent-Viry M; Galteau MM; Jacqz-Aigrain E; Krishnamoorthy R
Hum Genet; 1993 Oct; 92(4):367-72. PubMed ID: 7901140
[TBL] [Abstract][Full Text] [Related]
28. Mutation frequencies of the cytochrome CYP2D6 gene in Parkinson disease patients and in families.
Lucotte G; Turpin JC; Gérard N; Panserat S; Krishnamoorthy R
Am J Med Genet; 1996 Jul; 67(4):361-5. PubMed ID: 8837703
[TBL] [Abstract][Full Text] [Related]
29. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes.
Kagimoto M; Heim M; Kagimoto K; Zeugin T; Meyer UA
J Biol Chem; 1990 Oct; 265(28):17209-14. PubMed ID: 2211621
[TBL] [Abstract][Full Text] [Related]
30. Interpretation of a simple PCR analysis of the CYP2D6(A) and CYP2D6(B) null alleles associated with the debrisoquine/sparteine genetic polymorphism.
Douglas AM; Atchison BA; Somogyi AA; Drummer OH
Pharmacogenetics; 1994 Jun; 4(3):154-8. PubMed ID: 7920695
[No Abstract] [Full Text] [Related]
31. An inactive cytochrome P450 CYP2D6 allele containing a deletion and a base substitution.
Daly AK; Leathart JB; London SJ; Idle JR
Hum Genet; 1995 Mar; 95(3):337-41. PubMed ID: 7868129
[TBL] [Abstract][Full Text] [Related]
32. Correlation of polymorphic expression of CYP2D6 mRNA in bladder mucosa and tumor tissue to in vivo debrisoquine hydroxylase activity.
Romkes-Sparks M; Mnuskin A; Chern HD; Persad R; Fleming C; Sibley GN; Smith P; Wilkinson GR; Branch RA
Carcinogenesis; 1994 Sep; 15(9):1955-61. PubMed ID: 7923590
[TBL] [Abstract][Full Text] [Related]
33. Determination of dextromethorphan metabolic phenotype by salivary analysis with a reference to genotype in Chinese patients receiving renal hemodialysis.
Hou ZY; Chen CP; Yang WC; Lai MD; Buchert ET; Chung HM; Pickle LW; Woosley RL
Clin Pharmacol Ther; 1996 Apr; 59(4):411-7. PubMed ID: 8612385
[TBL] [Abstract][Full Text] [Related]
34. Debrisoquine hydroxylase and Parkinson's disease.
Kondo I; Kanazawa I
Adv Neurol; 1993; 60():338-42. PubMed ID: 8420147
[TBL] [Abstract][Full Text] [Related]
35. Debrisoquine hydroxylase (CYP2D6) and prostate cancer.
Febbo PG; Kantoff PW; Giovannucci E; Brown M; Chang G; Hennekens CH; Stampfer M
Cancer Epidemiol Biomarkers Prev; 1998 Dec; 7(12):1075-8. PubMed ID: 9865424
[TBL] [Abstract][Full Text] [Related]
36. Functional analysis of CYP2D6.31 variant: homology modeling suggests possible disruption of redox partner interaction by Arg440His substitution.
Allorge D; Bréant D; Harlow J; Chowdry J; Lo-Guidice JM; Chevalier D; Cauffiez C; Lhermitte M; Blaney FE; Tucker GT; Broly F; Ellis SW
Proteins; 2005 May; 59(2):339-46. PubMed ID: 15726636
[TBL] [Abstract][Full Text] [Related]
37. DNA haplotype-dependent differences in the amino acid sequence of debrisoquine 4-hydroxylase (CYP2D6): evidence for two major allozymes in extensive metabolisers.
Panserat S; Mura C; Gérard N; Vincent-Viry M; Galteau MM; Jacqz-Aigrain E; Krishnamoorthy R
Hum Genet; 1994 Oct; 94(4):401-6. PubMed ID: 7927337
[TBL] [Abstract][Full Text] [Related]
38. A novel CYP2D6 allele with an abolished splice recognition site associated with the poor metabolizer phenotype.
Marez D; Sabbagh N; Legrand M; Lo-Guidice JM; Boone P; Broly F
Pharmacogenetics; 1995 Oct; 5(5):305-11. PubMed ID: 8563771
[TBL] [Abstract][Full Text] [Related]
39. Genetic polymorphism of CYP2D6 in the Japanese population.
Chida M; Yokoi T; Kosaka Y; Chiba K; Nakamura H; Ishizaki T; Yokota J; Kinoshita M; Sato K; Inaba M; Aoki Y; Gonzalez FJ; Kamataki T
Pharmacogenetics; 1999 Oct; 9(5):601-5. PubMed ID: 10591540
[TBL] [Abstract][Full Text] [Related]
40. Ultrarapid metabolism of sparteine: frequency of alleles with duplicated CYP2D6 genes in a Danish population as determined by restriction fragment length polymorphism and long polymerase chain reaction.
Bathum L; Johansson I; Ingelman-Sundberg M; Hørder M; Brøsen K
Pharmacogenetics; 1998 Apr; 8(2):119-23. PubMed ID: 10022749
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
